These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28468948)

  • 1. The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.
    Wilmott JS; Rizos H; Scolyer RA; Long GV
    Clin Cancer Res; 2017 Jun; 23(12):2921-2923. PubMed ID: 28468948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophages Promote Resistance to Checkpoint Inhibitors.
    Cancer Discov; 2017 Aug; 7(8):788. PubMed ID: 28615281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.
    Lim SY; Rizos H
    Mamm Genome; 2018 Dec; 29(11-12):866-878. PubMed ID: 29968076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
    Wang Q; Wu X
    Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
    Colombo MP
    Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shed it, and help-LAG3 cleavage drives conventional CD4
    Seidel L; Bengsch B
    Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Approaches to Understanding Response and Resistance to Immunotherapy.
    Braun DA; Burke KP; Van Allen EM
    Clin Cancer Res; 2016 Dec; 22(23):5642-5650. PubMed ID: 27698000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.
    Dolan DE; Gupta S
    Cancer Control; 2014 Jul; 21(3):231-7. PubMed ID: 24955707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.
    Ascierto ML; Makohon-Moore A; Lipson EJ; Taube JM; McMiller TL; Berger AE; Fan J; Kaunitz GJ; Cottrell TR; Kohutek ZA; Favorov A; Makarov V; Riaz N; Chan TA; Cope L; Hruban RH; Pardoll DM; Taylor BS; Solit DB; Iacobuzio-Donahue CA; Topalian SL
    Clin Cancer Res; 2017 Jun; 23(12):3168-3180. PubMed ID: 28193624
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
    Luo M; Fu L
    Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of PD-1 blockade in tumors with MMR deficiency.
    Lee V; Le DT
    Immunotherapy; 2016; 8(1):1-3. PubMed ID: 26643016
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
    Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
    Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to overcome resistance to PD-1 inhibitors.
    Gajewski TF
    Clin Adv Hematol Oncol; 2020 May; 18(5):270-272. PubMed ID: 32628654
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to PD1/PDL1 checkpoint inhibition.
    O'Donnell JS; Long GV; Scolyer RA; Teng MW; Smyth MJ
    Cancer Treat Rev; 2017 Jan; 52():71-81. PubMed ID: 27951441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy].
    Hatae R; Chamoto K
    Rinsho Ketsueki; 2016; 57(10):2224-2231. PubMed ID: 27795534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death 1 immune checkpoint inhibitors.
    Trivedi MS; Hoffner B; Winkelmann JL; Abbott ME; Hamid O; Carvajal RD
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):858-68. PubMed ID: 27058852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are there, or shall we discover, biomarkers to guide PD-1 inhibition?
    Ascierto PA; de Mello RA
    Immunotherapy; 2016 Jun; 8(6):681-6. PubMed ID: 27197537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors for cancer treatment.
    Park J; Kwon M; Shin EC
    Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.